Pulling SEC filings + quote and writing the call…
Pulling SEC filings + quote and writing the call…

Theravance Biopharma, Inc.
Next earnings Aug 10, 2026 · consensus $0.05 EPS, $22.2M rev
Last earnings +0.5% on 2026-05-07
Revenue grew 66.9% YoY.
Quality fundamentals and an attractive price line up (~370% below fair value) — the rarer case where both the business and the entry look good.
Sources: SEC EDGAR (CIK 0001583107, latest 10-Q filed 2026-05-07) · EODHD · as of 6/22/2026, 2:26:47 PM.
Research and education only — not financial advice. Calls are generated from SEC filings and a delayed/third-party price feed, may be wrong or out of date, and are not a recommendation to buy or sell any security. Do your own research.
Theravance Biopharma, Inc. shows $107M in FY2025 revenue (+66.9% YoY), a 98.5% net margin, and 35.7% ROE.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $55.3M | $51.3M | $57.4M | $64.4M | $107M |
| Gross profit | — | — | — | — | — |
| Operating income | -$258M | -$92.0M | -$56.0M | -$46.9M | -$3.60M |
| Net income | -$199M | $872M | -$55.2M | -$56.4M | $106M |
| Diluted EPS | -$2.87 | $11.85 | -$1.00 | -$1.15 | $2.06 |
| Net margin | -360.6% | 1698.5% | -96.1% | -87.6% | 98.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosed under the STOCK Act
Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.
1483 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.
Last 90 days: 0 open-market buys · 3 sales
| 2026-06-15 | Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS | Sell | 3.33K @ $16.39 | $54.6K |
| 2026-06-15 | Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS | Sell | 3.33K @ $16.38 | $54.5K |
| 2026-06-15 | Farnum Rhonda SVP, COMM & MEDICAL AFFAIRS | Sell | 6.66K @ $16.39 | $109K |
| 2026-06-12 | Smaldone Alsup Laurie Director | Award | 6.01K | |
| 2026-06-12 | GRAY SUSANNAH Director | Award | 6.01K | |
| 2026-06-12 | MITCHELL DEAN J Director | Award | 6.01K | |
| 2026-06-12 | O'Connor Donal Director | Award | 6.01K | |
| 2026-06-12 | PAKIANATHAN DEEPIKA Director | Award | 6.01K | |
| 2026-05-20 | Winningham Rick E CHIEF EXECUTIVE OFFICER | Tax | 20.0K @ $16.55 | $332K |
| 2026-05-20 | Sawaf Aziz SVP & CHIEF FINANCIAL OFFICER | Tax | 8.67K @ $16.55 | $143K |